Alembic Pharma Gets USFDA Nod To Market Heart Failure Drug

Alembic Pharma Gets USFDA Nod To Market Heart Failure Drug

The company has received final approval from the US Food & Drug Administration (USFDA) for Sacubitril and Valsartan Tablets in strengths of 24 mg/26 mg, 49 mg/51 mg, and 97 mg/103 mg, Alembic said in a regulatory filing.

PTIUpdated: Thursday, May 30, 2024, 04:36 PM IST
article-image

 Alembic Pharmaceuticals on Thursday said it has received approval from the US health regulator to market a generic medication used to treat certain types of heart failure.

The company has received final approval from the US Food & Drug Administration (USFDA) for Sacubitril and Valsartan Tablets in strengths of 24 mg/26 mg, 49 mg/51 mg, and 97 mg/103 mg, Alembic said in a regulatory filing.

The approved product is therapeutically equivalent to Novartis's Entresto tablets.

The approved product is therapeutically equivalent to Novartis's Entresto tablets. |

The approved product is therapeutically equivalent to Novartis's Entresto tablets.

Sacubitril and Valsartan tablets are indicated to reduce the risk of cardiovascular death and hospitalisation for heart failure in adult patients with chronic heart failure.

It is also indicated for the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in paediatric patients aged one year and older.

According to IQVIA, Sacubitril and Valsartan tablets have an estimated market size of USD 5.3 billion for twelve months ending March 2024.

According to IQVIA, Sacubitril and Valsartan tablets have an estimated market size of USD 5.3 billion for twelve months ending March 2024. |

According to IQVIA, Sacubitril and Valsartan tablets have an estimated market size of USD 5.3 billion for twelve months ending March 2024.

Shares of Alembic Pharma on Thursday ended 0.34 per cent down at Rs 942.95 apiece on the BSE. 

RECENT STORIES

Indian Telecom Companies Start Caller ID Display Trials To Mitigate Spam Menace: Report

Indian Telecom Companies Start Caller ID Display Trials To Mitigate Spam Menace: Report

Mahindra & Mahindra Shares Zoom Over 70% In 6 Months As Company Looks To Reinforce Its Position With...

Mahindra & Mahindra Shares Zoom Over 70% In 6 Months As Company Looks To Reinforce Its Position With...

Markets And Banks To Remain Shut On June 17 On Account Of Eid al-Adha

Markets And Banks To Remain Shut On June 17 On Account Of Eid al-Adha

Greater Noida Board Hikes Land Allocation Rates By 5.30% For FY25

Greater Noida Board Hikes Land Allocation Rates By 5.30% For FY25

Vastu Tips To Consider While Buying Home

Vastu Tips To Consider While Buying Home